Richard W. Paul & Associates’s Intellia Therapeutics NTLA Stock Holding History

Richard W. Paul & Associates’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2	Closed	-$23	–	458
2024 Q4	$23	Hold	2	–	–	﹤0.01%	508
2024 Q3	$41	Hold	2	–	–	﹤0.01%	499
2024 Q2	$45	Hold	2	–	–	﹤0.01%	490
2024 Q1	$55	Hold	2	–	–	﹤0.01%	504
2023 Q4	$61	Hold	2	–	–	﹤0.01%	492
2023 Q3	$63	Sell	2 -2	-50%	-$78	﹤0.01%	501
2023 Q2	$163	Sell	4 -6	-60%	-$243	﹤0.01%	520
2023 Q1	$373	Hold	10	–	–	﹤0.01%	513
2022 Q4	$349	Buy	+10	New	+$475	﹤0.01%	505

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Richard W. Paul & Associates's NTLA Position: Q1 2025 in Review

Richard W. Paul & Associates sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 2 shares — an estimated $23 sold.

Richard W. Paul & Associates first reported a position in NTLA in Q4 2022 and held it in 9 quarters. The position peaked at $373 in Q1 2023. 294 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

Richard W. Paul & Associates reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
Richard W. Paul & Associates sold 2 Intellia Therapeutics shares in Q1 2025, an estimated $23.
Richard W. Paul & Associates first reported a position in Intellia Therapeutics in Q4 2022 and held it in 9 quarters.
Richard W. Paul & Associates's Intellia Therapeutics position peaked at $373 in Q1 2023.
294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on Richard W. Paul & Associates's 13F filing for Q1 2025, filed 12 May 2025.